Are you in %country%? Do you want to visit our website in another language?

Nomination for the
Federal President’s Award
for Innovation
and Technology

Award information


Nomination for the Federal President’s Award
for Innovation and Technology

Award information

The team comprised of Stefan Vilsmeier, Claus Promberger and Prof. Cordula Petersen, MD receive Federal President’s Award for Innovation and Technology 2022 nomination for ExacTrac Dynamic® technology.



The team comprised of Stefan Vilsmeier, Claus Promberger and Prof. Cordula Petersen, MD
receive Federal President’s Award for Innovation and Technology 2022 nomination for ExacTrac Dynamic® technology.

About the Award

The Federal President’s Award for Innovation and Technology is awarded annually by the German Federal President. It honors outstanding technical, engineering and scientific achievements that can provide economic momentum for Germany.

In 2021 the researchers Uğur Şahin, Özlem Türeci, Christoph Huber and Katalin Karikó from the Mainz-based company, BioNTech, were awarded the Federal President’s Award for Innovation and Technology for their development of an mRNA vaccine against the coronavirus.

Tune in to watch the Federal President’s Award for Innovation and Technology ceremony in Berlin!

Wednesday, October 26th
10:15 PM Central European Time on ZDF



Learn more about the award  

About the Award

The Federal President’s Award for Innovation and Technology is awarded annually by the German Federal President. It honors outstanding technical, engineering and scientific achievements that can provide economic momentum for Germany.

In 2021 the researchers Uğur Şahin, Özlem Türeci, Christoph Huber and Katalin Karikó from the Mainz-based company, BioNTech, were awarded the Federal President’s Award for Innovation and Technology for their development of an mRNA vaccine against the coronavirus.

Tune in to watch the Federal President’s Award for Innovation and Technology ceremony in Berlin!

Wednesday, October 26th
10:15 PM Central European Time on ZDF

The Nominees

The Nominees

Our Technology

ExacTrac Dynamic

Lung cancer is the leading cause of cancer death worldwide,
claiming around 45,000 lives per year in Germany alone.

Oftentimes, lung cancer is not diagnosed until the disease has reached a more advanced stage because lung cancer symptoms can take longer to manifest and detect. Patients move during irradiation and, due to respiration, the tumor can also move irregularly. Until now, a safety area around the tumor — referred to as the motion envelope — has been irradiated along with the tumor. The motion envelope encompasses the entire space in which the tumor moves during respiration. However, this approach can result in the destruction of healthy lung tissue, which ultimately can impair function and quality of life.

In addition, 2D X-Rays may not always be able to detect small and often treatable tumors. If these small lung tumors could be detected and treated in an early stage of disease progression, the patient’s chances of survival may increase.

Present and future of radiotherapy treatment

ExacTrac Dynamic was developed to address these challenges and limitations. With this technology, patients with different tumor types can be positioned with submillimetric precision during irradiation.

As a result, it is now possible to effectively destroy tumor tissue while sparing healthy tissue.

The potential of the technology is enormous—currently, ExacTrac Dynamic enables medical professionals to achieve high precision, submillimetric radiotherapy positioning for breast, brain, spine and prostate cancer patients. This supports the significantly more precise delivery of radiation therapy in fewer sessions than conventional radiation treatment and contributes to better quality of life for patients.

ExacTrac Dynamic is in the process of being modified so that in the future, it will be able to precisely target other types of solid tumors, including small, moving lung tumors.

For the development of this groundbreaking approach in lung cancer, Stefan Vilsmeier and Claus Promberger are in close collaboration with Prof. Cordula Petersen, whose clinical insights were incorporated into the project.

Learn more about treatment
with ExacTrac technology

More information 

Learn more about
Lung Motion Management

More information 

From diagnosis to treatment – learn more about patient positioning with state-of-the-art imaging technology in this video

Our Technology

ExacTrac Dynamic

Lung cancer is the leading cause of cancer death worldwide,
claiming around 45,000 lives per year in Germany alone.

Oftentimes, lung cancer is not diagnosed until the disease has reached a more advanced stage because lung cancer symptoms can take longer to manifest and detect. Patients move during irradiation and, due to respiration, the tumor can also move irregularly. Until now, a safety area around the tumor — referred to as the motion envelope — has been irradiated along with the tumor. The motion envelope encompasses the entire space in which the tumor moves during respiration. However, this approach can result in the destruction of healthy lung tissue, which ultimately can impair function and quality of life.

In addition, 2D X-Rays may not always be able to detect small and often treatable tumors. If these small lung tumors could be detected and treated in an early stage of disease progression, the patient’s chances of survival may increase.

Present and future of radiotherapy treatment

ExacTrac Dynamic was developed to address these challenges and limitations. With this technology, patients with different tumor types can be positioned with submillimetric precision during irradiation.

As a result, it is now possible to effectively destroy tumor tissue while sparing healthy tissue.

The potential of the technology is enormous—currently, ExacTrac Dynamic enables medical professionals to achieve high precision, submillimetric radiotherapy positioning for breast, brain, spine and prostate cancer patients. This supports the significantly more precise delivery of radiation therapy in fewer sessions than conventional radiation treatment and contributes to better quality of life for patients.

ExacTrac Dynamic is in the process of being modified so that in the future, it will be able to precisely target other types of solid tumors, including small, moving lung tumors.

For the development of this groundbreaking approach in lung cancer, Stefan Vilsmeier and Claus Promberger are in close collaboration with Prof. Cordula Petersen, whose clinical insights were incorporated into the project.

Learn more about treatment
with ExacTrac technology

More information 

Learn more about
lung motion management

More information 


From diagnosis to treatment – learn more about patient positioning with state-of-the-art imaging technology in this video